These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32214208)

  • 21. Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against
    Gao P; Davies J; Kao RYT
    mBio; 2017 Sep; 8(5):. PubMed ID: 28874472
    [No Abstract]   [Full Text] [Related]  

  • 22. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers.
    Shepard TY; Jensen DR; Blotner S; Zhi J; Guerciolini R; Pace D; Eckel RH
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):187-94. PubMed ID: 10702769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
    Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
    Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Obesity Effect of Arq Zeera and Its Main Components Thymol and Cuminaldehyde in High Fat Diet Induced Obese Rats.
    Haque MR; Ansari HS
    Drug Res (Stuttg); 2018 Nov; 68(11):637-647. PubMed ID: 29635674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating the release of pharmaceuticals from lipid cubic phases using a lipase inhibitor.
    Dully M; Brasnett C; Djeghader A; Seddon A; Neilan J; Murray D; Butler J; Soulimane T; Hudson SP
    J Colloid Interface Sci; 2020 Aug; 573():176-192. PubMed ID: 32278949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient.
    Nägele H; Petersen B; Bonacker U; Rödiger W
    Eur J Clin Pharmacol; 1999 Nov; 55(9):667-9. PubMed ID: 10638396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of adiposity and related metabolic disturbances by polyphenol-rich extract of Boswellia serrata gum through alteration of adipo/cytokine profiles.
    Gomaa AA; Farghaly HSM; El-Sers DA; Farrag MM; Al-Zokeim NI
    Inflammopharmacology; 2019 Jun; 27(3):549-559. PubMed ID: 30069718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sesquiterpene farnesol as a competitive inhibitor of lipase activity of Staphylococcus aureus.
    Kuroda M; Nagasaki S; Ito R; Ohta T
    FEMS Microbiol Lett; 2007 Aug; 273(1):28-34. PubMed ID: 17559400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine.
    Sternby B; Hartmann D; Borgström B; Nilsson A
    Clin Nutr; 2002 Oct; 21(5):395-402. PubMed ID: 12381337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review.
    Hao X; Zhu X; Tian H; Lai G; Zhang W; Zhou H; Liu S
    Medicine (Baltimore); 2023 Sep; 102(36):e34671. PubMed ID: 37682175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Tetrahydrolipstatin and Stereoderivatives on the Inhibition of Essential Mycobacterium tuberculosis Lipid Esterases.
    Goins CM; Sudasinghe TD; Liu X; Wang Y; O'Doherty GA; Ronning DR
    Biochemistry; 2018 Apr; 57(16):2383-2393. PubMed ID: 29601187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orlistat inhibits dietary cholesterol absorption.
    Mittendorfer B; Ostlund RE; Patterson BW; Klein S
    Obes Res; 2001 Oct; 9(10):599-604. PubMed ID: 11595776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug treatment of obesity.
    Bray GA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
    Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structures of Staphylococcus aureus peptide deformylase in complex with two classes of new inhibitors.
    Lee SJ; Lee SJ; Lee SK; Yoon HJ; Lee HH; Kim KK; Lee BJ; Lee BI; Suh SW
    Acta Crystallogr D Biol Crystallogr; 2012 Jul; 68(Pt 7):784-93. PubMed ID: 22751663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
    Nelson RH; Miles JM
    Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.